← Oncology Approval Tracker

FDA DECISION ·

Stimufend

pegfilgrastim-fpgk · Fresenius Kabi

Biosimilar approvalBiosimilarChemotherapy-associated febrile neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Pegfilgrastim biosimilar for reducing infection manifested as febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy with a clinically significant risk.

LAMPGEN ANALYSIS

Why it matters

The product expands long-acting G-CSF supply options for eligible regimens.

What research teams should watch

Check presentation, traceability and chemotherapy-cycle timing when incorporating the product into supportive care orders.

PRIMARY RECORDS

Sources